Patents Examined by Dennis Heyer
  • Patent number: 10463632
    Abstract: A method of preventing and/or treating a disease caused by diabetes complications includes administering to a patient in need thereof, an effective amount of thymoquinone or a pharmaceutically acceptable salt thereof, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excipient. The disease can be at least one of retinopathy, nephropathy, neuropathy, and neurological disorder.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 5, 2019
    Assignee: King Saud University
    Inventors: Khalid Mohammed Alkharfy, Ghulam Mohammad, Ajaz Ahmad, Mohammad Mairaj Siddiquei, Ahmed Abu El-Asrar
  • Patent number: 10463736
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: November 5, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10456471
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: October 29, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10456386
    Abstract: The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal application.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 29, 2019
    Assignee: OTOLANUM AG
    Inventors: Christopher John Wraight, Thomas Meyer
  • Patent number: 10457666
    Abstract: Crystal Form I of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting powder X-ray peaks at two or more angles selected from the group consisting of 11.6°, 17.2°, 17.8°, 23.3°, 27.1°, and 29.3° as a diffraction angle (2?±0.2°).
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 29, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Kazuno, Tomonobu Mutsumi
  • Patent number: 10449197
    Abstract: Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is LKB 1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a G2/M checkpoint inhibitor.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: October 22, 2019
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Timothy G. Whitsett, Jr., Landon J. Inge
  • Patent number: 10450285
    Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 22, 2019
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Andrew David Westwell, Andrea Brancale, Richard William Ernest Clarkson, Jitka Soukupova
  • Patent number: 10441590
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 15, 2019
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • Patent number: 10438688
    Abstract: An in silico screening method generated compounds that are against laminin receptor 37LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC50 value that can have relevant clinical use for prostate cancer or osteoarthritis.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Purdue Research Foundation
    Inventors: Marxa L. Figueiredo, Charles Samuel Umbaugh, Herman O. Sintim, Adriana Diaz-Quinones
  • Patent number: 10426839
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 1, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10420760
    Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 24, 2019
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Jeffrey M. Moshal, Michael Libman
  • Patent number: 10408838
    Abstract: Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: September 10, 2019
    Assignee: NYU Winthrop Hospital
    Inventor: Louis Ragolia
  • Patent number: 10406165
    Abstract: The present invention provides modulators of protein function, to restore protein homeostasis, including GSPT1 activity. The invention provides methods of modulating protein-mediated diseases, such as GSPT1-mediated diseases, disorders, conditions, or responses. Compositions are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as GSPT1-mediated diseases, disorders, and conditions, including cancer and astrogliosis.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: September 10, 2019
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan
  • Patent number: 10398712
    Abstract: Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: September 3, 2019
    Assignee: Vitalis LLC
    Inventor: Joseph Habboushe
  • Patent number: 10392375
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • Patent number: 10383884
    Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2019
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
  • Patent number: 10376481
    Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 13, 2019
    Assignee: ARDELYX, INC.
    Inventors: Noah Bell, Christopher Carreras, Michael Robert Leadbetter, Jason Gustaf Lewis, Jeffrey W. Jacobs, Irina Dotsenko, Dean Dragoli, Ying He, Andrew King, Matthew Siegel
  • Patent number: 10376487
    Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: August 13, 2019
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
  • Patent number: 10376510
    Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 13, 2019
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins
  • Patent number: 10369158
    Abstract: This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: August 6, 2019
    Assignee: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl